You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
复星医药(02196.HK)拟设立新药创新基金 首期募资规模超10亿元人币
阿思达克 10-17 09:52

复星医药(02196.HK)公布,与苏州吴中经济技术开发区管理委员会及苏州市吴中金融控股集团签订《战略合作框架协议》,就参与投资设立新药创新基金等达成合作意向。

新药创新基金拟由复星医药发起募集设立,首期募集资金规模约10亿至15亿元人民币。

根据框架协议合作内容包括:新药创新基金与其GP拟落地在吴中经开区;吴中经开区(通过引导基金)、吴中金控拟以有限合夥人身份参与投资新药创新基金,合计出资额不超过新药创新基金募资总规模的32%;新药创新基金投资到落户於吴中经开区的项目公司的总金额不低於人民币3.2亿元;吴中经开区同意为复星医药或其关联方预留其生物医药产业园内的100亩土地,具体区域与价格将由双方进一步商议,同时吴中经开区将为新药创新基金及其落地项目提供各项优惠政策,包括但不限於场地、人才引进、税收等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account